May 17th 2024
Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
2021's Breakthroughs & Disappointments
December 23rd 2021The past year gave dermatologists ample cause for both celebration and frustration as they looked forward to new drugs, devices, and technology to optimize patient care. Here, Dermatology Times® editorial advisory board members weigh in on the good, bad, and still-TBD changes that shaped the specialty during 2021.
New Roflumilast Vehicle Data Announced
December 13th 2021Arcutis Biotherapeutics has announced data suggesting that the vehicle in the investigational roflumilast cream had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema.
Galderma, Sofregen Enter Agreement to Develop Silk-based Biostimulators
September 28th 2021Galderma and Sofregen Medical announced they have entered into an agreement to co-develop a novel line of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.
Topical Remetinostat Effective, Tolerable in Basal Cell Carcinoma
September 16th 2021The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.